USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
29 Jun 2022 | 02:45 PM GMT

What’s in Remote Patient Monitoring programs for Pharma?

Anchored by:

Brian Flatley
VP Consulting Services & US Pharma Solutions
S3 CONNECTED HEALTH

Participants:

Brian Flatley VP Consulting Services & US Pharma SolutionsS3 Connected Health
Brian Flatley
VP Consulting Services & US Pharma SolutionsS3 Connected Health
Brian Mahony Medical Research FellowBioinnovate
Brian Mahony
Medical Research FellowBioinnovate
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
ES
Ekaterina Ser DirectorMSD
ES
Ekaterina Ser
DirectorMSD
NC
Navin Cooray Oxehealth
NC
Navin Cooray
Oxehealth
Reginald Swift Founder & CEORubix LS
Reginald Swift
Founder & CEORubix LS
Thiru Kanagasabapathi Head of Digital Health External InnovationsBiogen
Thiru Kanagasabapathi
Head of Digital Health External InnovationsBiogen

About this Meeting

As the Covid-19 pandemic shifted how people interact with healthcare, the relationship between pharma and patients changed as many moved away from conventional clinical settings. This coincided with the proliferation of a vast range of technological solutions - from apps to wearable sensors and at-home devices - that gave patients a lot of ways to relay information. Remote patient monitoring (RPM) has vast potential, yet it is still very new with many issues that need to be ironed out.  

Join us to break down the opportunities for pharma and the steps required to successfully commercialize and/or create value through RPM:  

  • Hospitals and payers seem to be the preferred routes for RPM companies, but there are interesting use cases of RPM within pharma around monitoring in clinical trials and post-market surveillance. What has worked so far and what can pharma build on (decentralized clinical trials, chronic disease management, etc.)?  
  • Integrating into clinicians’ workflows and protocols will be critical to driving adoption. What role can pharma play here and where can it derive value? 
  • What can RPM bring to pharma in a commercial sense? Is it a revenue driver, a patient retention tool, a cost-saving mechanism, or a data source to inform market intelligence and research and development (R&D) teams? A combination of all of these?  
  • How can RPM manufacturers demonstrate the value to pharma companies? What speech works and who to talk to?